


英文原版

Molecular Neuropharmacology

A Foundation for Clinical Neuroscience

分子神经药理学



Eric J. Nestler
Steven E. Hyman
Robert C. Malenka



人民卫生出版社



McGraw-Hill

Molecular Neuropharmacology:

A Foundation for Clinical Neuroscience

Eric J. Nestler, MD, PhD

*Lou and Ellen McGinley Distinguished Professor
and Chairman*

Department of Psychiatry

*The University of Texas Southwestern Medical Center at Dallas
Dallas, Texas*

Steven E. Hyman, MD

National Institutes of Health

Bethesda, Maryland

Robert C. Malenka, MD, PhD

*Nancy Friend Pritzker Professor of Psychiatry
and Behavioral Sciences*

Director, Nancy Friend Pritzker Laboratory

Department of Psychiatry and Behavioral Sciences

Stanford University School of Medicine

Palo Alto, California

人民卫生出版社

McGraw-Hill

人民卫生出版社
McGraw-Hill

A Division of The McGraw-Hill Companies



MOLECULAR NEUROPHARMACOLOGY

Copyright © 2001 by the McGraw-Hill Companies, Inc.
All rights reserved. Printed in the United States of America.
Except as permitted under the United States
Copyright Act of 1976, no part of this publication may be
reproduced or distributed in any form or by any means,
or stored in a data base or retrieval system, without the
prior written permission of the publisher.

*Cover illustration: Trafficking and Ca^{2+} —dependent exocytosis
of a norepinephrine-containing synaptic vesicle is depicted.*

This book was set in New Baskerville by V&M Graphics.
The editors were Janet Foltin, Harriet Lebowitz,
and Karen G. Edmonson.

The production supervisor was Catherine H. Saggese.

The index was prepared by Kathryn Unger.

The text was designed by Joan O'Connor.

The cover was designed by Eve Siegel.

The illustration manager was Charissa Baker.

Quebecor Printing/Kingsport was printer and binder.

This book is printed on acid-free paper.

Nestler, Eric J. (Eric Jonathan). 1954—

Molecular neuropharmacology: a foundation for clinical neuro-
science / Eric J. Nestler, Steven E. Hyman, Robert C. Malenka.—
1st ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 0-8385-6379-1

1. Neuropharmacology. 2. Molecular neurobiology. I. Hyman,
Steven E. II. Malenka, Robert C. III. Title.

[DNLM: 1. Central Nervous System Agents—pharmacology.
2. Central Nervous System—drug effects. 3. Central Nervous
System—physiology. 4. Central Nervous System Diseases—drug
therapy. QV 76.5 N468m 2001]
RD315.N455 2001
617'.78—dc21

00-051549

ISBN: 0-07-112065-3 (international)

Exclusive rights by The McGraw-Hill Companies, Inc., for
manufacture and export. This book cannot be re-exported
from the country to which it is consigned by McGraw-Hill.
The International Edition is not available in North America.

图字: 01-2001-3621

分子神经药理学 (英文版)

编 著: Eric J. Nestler

出版发行: 人民卫生出版社(中继线 67616688)

地 址: (100078) 北京市丰台区方庄芳群园
3区3号楼

网 址: <http://www.pmph.com>

E-mail: pmph@pmph.com

印 刷: 北京人卫印刷厂

经 销: 新华书店

开 本: 880×1230 1/16 印张: 35

字 数: 1473千字

版 次: 2001年11月第1版

2001年11月第1版第1次印刷

标准书号: ISBN 7-117-04564-7/R·4565

定 价: 126.00元

著作权所有, 请勿擅自用本书制作各类出版物, 违者必究

(凡属质量问题请与本社发行部联系退换)

Molecular Neuropharmacology:

A Foundation for Clinical Neuroscience

Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The editors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the editors, authors, nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this book is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

This book is dedicated

to our wives and children:

Susan, David, Matt, and Jane

Barbara, Emily, Julia, and Charlie

Pam, Nick, and Ben

CONTRIBUTING AUTHORS

JOHN ALVARO, PhD

*Yale University School of Medicine
New Haven, Connecticut*

JENNIFER A. CUMMINGS, MA

University of California, San Francisco

GATHARINE DUMAN, PhD

*Yale University School of Medicine
New Haven, Connecticut*

CHARLES GLATT, MD, PhD

University of California, San Francisco

KELLY VAN KOUGHNET, PhD

*Canadian Institutes of Health Research
Ottawa, Ontario*

DAVID KRANTZ, MD, PhD

University of California, Los Angeles

CHRIS McBAIN, PhD

*National Institute of Child Health & Development
Bethesda, Maryland*

THOMAS NEYLAN, MD

University of California, San Francisco

HEATHER RIEFF, PhD

*University of Virginia Medical Center
Charlottesville, Virginia*

NICOLE ULLRICH, MD, PhD

*Children's Hospital and Harvard Medical School
Boston, Massachusetts*

DAN WOLF, MD, PhD

*Yale University School of Medicine
New Haven, Connecticut*

PREFACE

Neuropharmacology, the study of drug actions on the nervous system, comprises several areas of investigation of critical importance to science and medicine. Neuropharmacology involves studies aimed at understanding the mechanisms by which drugs alter brain function. These include medications used to treat a wide range of neurologic and psychiatric disorders as well as drugs of abuse. A primary goal of neuropharmacology is to use this information to develop new medications with ever-improving efficacy and safety for diseases of the nervous system. In addition, neuropharmacologic agents are valuable tools with which to probe the molecular and cellular basis of nervous system functioning. For example, the mechanisms of drugs that produce their clinically relevant effects only after repeated administration, agents such as antidepressants in treating depression or drugs of abuse in causing addiction, provide a means of learning about neural plasticity. Overall, much of what we now know about the nervous system—how individual neurons work, how neurons communicate with one another, and how neurons adapt over time to external stimuli—has come from studies using pharmacologic probes.

To comprehend the actions of a drug on the nervous system, a great deal more is needed than simply identifying the drug's initial target in the nervous system. Rather, one must understand the entire sequence of events that commences with the binding of a drug to an initial molecular target. The resulting alteration in the functioning of that target, the influence of that occurrence on the complex biochemical networks that exist within neurons, the subsequent changes in the output of the neuron, and their consequences for the functioning of circuits within which the targeted neu-

ron exists are all important for gaining a real understanding of drug action. Only with an awareness of the many steps in the process can we grasp how a drug changes complex nervous system functions such as movement, cognition, pain, or mood. Thus, the action of a drug on the nervous system must be comprehended at many levels under both normal and pathologic conditions.

The organization of this textbook represents an attempt to build an understanding of drug action by adding the different levels of explanation layer by layer. As a result this book differs significantly from many other pharmacology texts, which are usually organized drug by drug or neurotransmitter by neurotransmitter. In this book, information on fundamental molecular and cellular building blocks is provided first so that it can serve as the basis for the material associated with neural functions. This permits the reader to relate fundamental neuropharmacology to neural systems and ultimately to clinical neuroscience.

The book is divided into three parts. Part 1 includes a brief discussion of general principles of neuropharmacology (Chapter 1), followed by a detailed presentation of nervous system function (Chapters 2–6), from electrical excitability to signal transduction to gene expression. Drugs that act on these basic components of neuronal function are mentioned in these early chapters.

In Part 2 information about the major neurotransmitter systems in the brain and spinal cord is presented (Chapters 7–10). Highlighted in these chapters are the molecular details of neurotransmitter synthetic and degradative enzymes, receptors, and transporter proteins. These proteins represent the initial targets for the large majority of known psychotropic drugs. Also

included in Part 2 is a discussion of neurotrophic factors (Chapter 11), which over the last 10 years have been shown to profoundly influence the adult nervous system and to be potentially important in therapeutics.

Part 3 uses the basic information contained in Parts 1 and 2 to build a systems-level description of the major domains of complex nervous system function. Chapter 12 focuses on the autonomic nervous system; Chapter 13 on neuroendocrine function, Chapter 14 on movement, Chapter 15 on emotion and mood, Chapter 16 on reinforcement and addiction, Chapter 17 on higher cognitive function and psychosis, Chapter 18 on attention and sleep, Chapter 19 on pain, Chapter 20 on memory and dementia, and Chapter 21 on stroke and seizures. Each chapter begins with a description of the normal neural mechanisms underlying a particular domain of nervous system functioning, followed by a discussion of the diseases that affect that domain. Drugs are discussed within the context of their influence on the neural circuits involved in both normal function and specific disease states.

The organization of *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience* allows individual drugs to be discussed in several contexts. A drug is first mentioned when its initial target is described in Parts 1 or 2. The drug is mentioned again in Part 3 in the context of its effect on complex neural functions. Many drugs are discussed in several chapters of Part 3 because they affect more than one domain; for example, first-generation antipsychotic drugs not only reduce psychosis (Chapter 17), but also affect motor function (Chapter 14) and sleep (Chapter 18).

The book's structure also permits the incorporation of a great deal of clinical information, much of it representing the integration of modern molecular genetics with neuropharmacology. New insights on the molecular mechanisms underlying such disorders as Parkinson disease, Huntington disease, depression, schizophrenia, Alzheimer disease, stroke, and epilepsy,

to name a few, are provided. Our knowledge of the molecular underpinnings of normal brain function and disease, particularly in cases that have been successfully investigated by genetics, may be in advance of developments in pharmacology. Consequently, the book includes many molecular insights, even though drugs may not yet exist that exploit such molecular knowledge. In this regard the book can be seen as presenting a template for the future in identifying molecular mechanisms for novel therapeutic approaches. We anticipate that subsequent editions of this book will describe the development of such novel medications and thereby gradually fill in these gaps in pharmacology.

The scientific and clinical explanations in *Molecular Neuropharmacology: A Foundation for Clinical Neuroscience* are written in a style that makes them accessible to a wide audience: undergraduate and graduate students as well as students in the medical and allied health professions. This book is also an excellent resource for residents in psychiatry, neurology, and anesthesiology, and practicing clinicians and scientists in these areas. As a concise treatise of clinical information that provides descriptions of basic mechanisms and their clinical relevance, this book is suitable for both scientists and clinicians.

We would like to acknowledge the contributing authors who were instrumental in the initial phases of the preparation of this book. We also would like to thank Harvey Shoolman who originally recruited us for this project; Georgia Miller, who was an enormous help in numerous ways; and the folks at McGraw-Hill—Harriet Lebowitz, Janet Foltin, Pam Carley, Eve Siegel, and Susan Worley—who whipped this book (and us) into shape.

Eric J. Nestler
Steven E. Hyman
Robert C. Malenka

CONTENTS

Contributing Authors
Preface

xiii
xv

PART 1. FUNDAMENTALS OF NEUROPHARMACOLOGY

1. BASIC PRINCIPLES OF NEUROPHARMACOLOGY

How Drugs Work
Drugs As Tools to Probe Brain Function
Principles of General Pharmacology
 Drug Binding
 Drug Efficacy
 Dose-Dependent Drug Response
 Drug Interaction With Nonreceptor Proteins
Neuropharmacology in the Molecular Era
 Molecular Diversity of the Brain

1
3
4
4
5
6
9
11
11
12
15

2. NEURONS AND GLIA

The Neuron
 The Cell Body
 The Axon
 Dendrites
 The Cytoskeleton and the Transport of Proteins
 The Synapse
Glia
 Astrocytes
 Oligodendrocytes and Schwann Cells
 Microglia
Cerebral Blood flow
Blood–Brain Barrier

17
20
20
22
23
23
25
27
27
28
28
29
29

3. ELECTRICAL EXCITABILITY OF NEURONS

Electrical Potential in Cells
 How Neurons Maintain Electrical Potential
 A Simple Cell Model
 A More Complicated Cell Model
 Maintenance of Resting Potential by ATP-Dependent Pumps
 Biophysical Properties of the Cell Membrane
 Sensory, Synaptic, and Action Potentials
Molecular Properties of Ion Channels
 The Prototypic Voltage-Gated Channel
 Voltage-Activated Opening of Ion Channels
 Voltage-Activated Closing of Ion Channels
Types of Ion Channels
 Sodium Channels
 Potassium Channels
 Calcium Channels
 Chloride Channels

34
35
35
36
37
38
39
40
44
44
46
47
48
48
50
53
55

4. SYNAPTIC TRANSMISSION

Neuronal Morphology
 Dendrites and Axons
 The Synapse
 Chemical Synaptic Transmission
 Storage and Release of Neurotransmitters
 Postsynaptic Signaling
 Fast Synaptic Transmission
 Slow Synaptic Transmission
 Receptor Subtypes
Neurotransmitter Storage, Reuptake, and Release
 The Role of Calcium Ions
 Quantal Release

59
60
60
61
61
61
62
64
66
65
65
65
66

<i>Packaging and Transport of Neurotransmitters</i>	67	<i>Transcription Factors:</i>	
<i>Termination of Neurotransmitter Action</i>	68	<i>Targets of Signaling Pathways</i>	125
<i>Synaptic Vesicles and Large Dense Core Vesicles</i>	69	<i>CREB Family of Transcription Factors</i>	126
<i>Vesicle Biosynthesis and Transport</i>	70	<i>AP-1 Family of Transcription Factors</i>	129
<i>Segregation of Vesicles</i>	70	<i>Steroid Hormone Receptor Superfamily</i>	134
Biochemistry of Neurotransmitter Release:		<i>Other Transcription Factors</i>	135
The Exocytotic Cycle	70		
<i>Proteins Involved in the Exocytotic Cycle</i>	72	PART 2. NEURAL SUBSTRATES	
<i>Endocytosis and Recycling</i>	80	OF DRUG ACTION	139
<i>Complexity and Specialization</i>	82		
5. SIGNAL TRANSDUCTION PATHWAYS		7. EXCITATORY AND INHIBITORY	
IN THE BRAIN	85	AMINO ACIDS	141
Overview of Signal Transduction Pathways	86	Glutamate	142
G Proteins and Second Messengers	88	<i>The Major Excitatory Neurotransmitter</i>	142
<i>G Proteins</i>	88	<i>Synthetic and Degradative Pathways</i>	142
<i>G Protein Regulation of Ion Channels</i>	91	<i>Release and Reuptake</i>	142
<i>Second Messengers</i>	92	<i>Glutamate Receptors</i>	144
Protein Phosphorylation: A Final Common		<i>Role of Glutamate in Neural Plasticity</i>	153
Pathway in the Regulation of Neuronal Function	99	<i>Role of Glutamate in Neuronal Toxicity</i>	153
<i>Second Messenger-Dependent Protein</i>		GABA	154
<i>Phosphorylation Cascades</i>	99	<i>Major Inhibitory Neurotransmitter in the Brain</i>	154
<i>Neurotrophic Factor-Regulated Protein</i>		<i>Synthetic and Degradative Pathways</i>	155
<i>Phosphorylation Cascades</i>	105	<i>Release and Reuptake</i>	156
<i>Other Protein Phosphorylation Cascades</i>	109	<i>GABA Receptors</i>	157
<i>Centrality of Protein Phosphorylation</i>	111	Glycine	162
Neuromodulators	112	<i>Synthetic and Degradative Pathways</i>	162
Heterogeneity in Brain Signal Transduction		<i>Glycine Release and Reuptake</i>	163
Pathways	112	<i>Glycine Receptors</i>	164
6. SIGNALING TO THE NUCLEUS	115	8. CATECHOLAMINES	167
Control of Gene Expression	116	Synthetic Pathways	168
<i>DNA Replication and Transcription</i>	116	<i>Tyrosine Hydroxylase</i>	170
<i>Regulation of Gene Expression by Chromatin</i>	117	Degradative Pathways	173
<i>Genes and the Genome</i>	117	<i>Monoamine Oxidase</i>	173
<i>Regulated Steps of Transcription</i>	117	<i>Catechol-O-Methyl Transferase</i>	173
<i>Alternative Splicing of Primary RNA Transcripts</i>	118	Functional Anatomy	173
<i>Regulation of mRNA Stability and Translatability</i>	120	<i>Norepinephrine</i>	173
<i>Translation of Mature mRNA in the Cytoplasm</i>	120	<i>Dopamine</i>	175
<i>Posttranslational Processing of Proteins</i>	121	Storage, Release, and Reuptake	177
Regulation of Transcription	121	<i>Plasma Membrane Transporters</i>	177
<i>Transcription Initiation:</i>		<i>Norepinephrine Transporter</i>	178
<i>A Critical Biologic Control Point</i>	121	<i>Dopamine Transporter</i>	179
<i>Core Promoters</i>	121	Receptors	180
<i>Transcription Factors:</i>		<i>Physiology of Catecholamine Receptors</i>	183
<i>Key Regulators of Gene Expression</i>	122	<i>Autoreceptors</i>	183
Regulation of Gene Expression		<i>Structural Features of G Protein-Coupled Receptors</i>	184
by Extracellular Signals	124	<i>Receptor Trafficking</i>	187
		<i>Receptor Distribution in the Brain</i>	187

9. SEROTONIN, ACETYLCHOLINE, AND HISTAMINE	191	<i>Neurotrophins and Synaptic Plasticity</i>	241
Serotonin	192	GDNF Family	242
<i>Synthetic and Degradative Pathways</i>	192	CNTF Family	243
<i>Functional Anatomy</i>	195	<i>CNTF Signaling Pathways</i>	244
<i>Storage, Release, and Reuptake</i>	196	Immune-Response Cytokines and the CNS	245
<i>Serotonin Receptors</i>	198	Chemokines	245
Acetylcholine	200	Neuronal Injury and Death	247
<i>Synthetic and Degradative Pathways</i>	201	<i>Oxidative Stress</i>	250
<i>Functional Anatomy</i>	202	PART 3. NEUROPHARMACOLOGY OF SPECIFIC NEURAL FUNCTIONS AND RELATED DISORDERS	253
<i>Storage, Release, and Reuptake</i>	203		
<i>Acetylcholine Receptors</i>	204	12. AUTONOMIC NERVOUS SYSTEM	255
Histamine	208	Anatomy of the Autonomic Nervous System	259
<i>Synthetic and Degradative Pathways</i>	208	<i>Sympathetic Nervous System</i>	259
<i>Functional Anatomy</i>	208	<i>Parasympathetic Nervous System</i>	260
<i>Histamine Receptors</i>	209	Neurotransmitters of the Autonomic Nervous System	260
10. NEUROPEPTIDES AND PURINES	213	<i>Principal Neurotransmitters</i>	260
Characteristics of Neuropeptides	214	<i>Neuropeptides</i>	260
<i>Precursor Proteins</i>	215	Pharmacology of the Autonomic Nervous System	261
<i>Proteolytic Processing</i>	215	<i>Ganglionic Stimulating and Blocking Agents</i>	261
<i>Generation of Diversity</i>	217	<i>Adrenergic Receptor Agonists and Antagonists</i>	263
<i>Storage and Release</i>	217	<i>Muscarinic Cholinergic Receptor Agonists and Antagonists</i>	266
<i>Long-Distance Signaling by Neuropeptides</i>	219	Central Control of the Autonomic Nervous System	267
<i>Receptor Types and Subtypes</i>	222	<i>Nucleus Tractus Solitarius</i>	267
<i>Neuropeptide Functions</i>	224	<i>Hypothalamus</i>	268
Neuropeptide Systems	225	<i>Other Control Centers</i>	269
<i>Opioid Peptides</i>	225	Disorders of the Autonomic Nervous System	269
<i>Corticotropin-Releasing Factor</i>	227	<i>Genetic Causes of Dysautonomia</i>	269
<i>Substance P</i>	227	<i>Systemic Diseases Associated With Autonomic Dysfunction</i>	273
<i>Neurotensin</i>	228	<i>Other Autonomic Syndromes</i>	275
<i>Neuropeptide Y</i>	228	<i>Experimental Models of Autonomic Neuropathy</i>	275
Purines	229	13. NEUROENDOCRINE CONTROL OF THE INTERNAL MILIEU	277
<i>Biochemistry</i>	229	Neuroendocrine Hypothalamus	278
<i>Storage and Release</i>	229	<i>Afferent Signals</i>	278
<i>Transporters</i>	229	<i>Efferent Signals</i>	279
<i>Receptors</i>	230	<i>Organization of the Hypothalamic-Pituitary Unit</i>	279
<i>Purine Functions</i>	232	Hypothalamic-Neurohypophyseal System	280
11. NEUROTROPHIC FACTORS	235	<i>Arginine Vasopressin</i>	280
Functional Characteristics of Neurotrophic Factors	236	<i>Oxytocin</i>	280
<i>Families of Neurotrophic Factors</i>	237	Hypothalamic-Pituitary-Adrenal Axis	281
Neurotrophins	238	<i>Corticotropin-Releasing Factor and Its Receptors</i>	282
<i>Trk Receptors</i>	239		
<i>The p75 Receptor</i>	240		
<i>Neurotrophin and Trk Receptor Knockout Mice</i>	240		

<i>ACTH and Glucocorticoids</i>	282	<i>Genetics of Mood Disorders</i>	341
<i>Glucocorticoid Synthesis</i>	282	<i>Neuroendocrine Abnormalities Associated</i>	
<i>Glucocorticoid Physiology</i>	282	<i>With Depression</i>	341
Hypothalamic–Pituitary–Thyroid Axis	286	<i>Anxiety Disorders and Depression</i>	342
<i>Function of the HPT Axis in Stress and Depression</i>	288	<i>Antidepressant Drugs</i>	342
Hypothalamic–Pituitary–Gonadal Axis	288	<i>Lithium and Other Mood-Stabilizing Drugs</i>	350
Prolactin	292		
Growth Hormone	294		
Control of Energy Balance and Appetite	295	16. REINFORCEMENT AND	
<i>Potential Pathways of Leptin Action</i>	297	ADDICTIVE DISORDERS	355
<i>Disorders of Appetite Control</i>	298		
Hypothalamic Response to Infection		Brain Reward Pathways	356
and Inflammation	299	<i>A Comparison Between Addictive Drugs</i>	
		<i>and Natural Reinforcers</i>	357
14. CONTROL OF MOVEMENT	303	<i>Functional Consequences of Long-Term</i>	
		<i>Drug Exposure</i>	357
Normal Control of Movement	304	<i>Reward Pathways: Anatomy and Neurochemistry</i>	358
<i>Anatomy of the Corticospinal Pathway</i>	304	Initial Actions of Drugs of Abuse	
<i>Anatomy of the Extrapyramidal System</i>	304	and Natural Reinforcers	360
<i>Cerebellar Control of Movement</i>	308	<i>Psychostimulants</i>	360
Disorders of Movement	309	<i>Opiates</i>	362
<i>Disorders of the Pyramidal Tract and Cerebellum</i>	310	<i>Ethanol</i>	364
<i>Parkinson Disease</i>	312	<i>Nicotine</i>	365
<i>Drug-Induced Parkinsonism</i>	314	<i>Cannabinoids</i>	365
<i>Treatment of Parkinson Disease</i>	317	<i>Phencyclidine</i>	366
<i>Essential Tremor</i>	319	<i>Other Drugs of Abuse</i>	366
<i>Huntington Disease</i>	320	<i>Activation of Reward Circuitry</i>	
<i>Dystonia</i>	322	<i>by Natural Reinforcers</i>	367
<i>Tourette Syndrome</i>	323	<i>Dopaminergic Neurons and</i>	
<i>Sydenham Chorea</i>	324	<i>Reward-Dependent Learning</i>	368
<i>Obsessive–Compulsive Disorder</i>	324	<i>Extended Reward Circuitry</i>	368
<i>Wilson Disease</i>	325	Molecular and Cellular Mechanisms of Addiction	369
		<i>Adaptations That Produce Tolerance</i>	
15. MOOD AND EMOTION	327	<i>and Physical Dependence</i>	370
		<i>Opiate Tolerance and Dependence</i>	370
Representation of Emotion in the Brain	328	<i>Emotional and Motivational Aspects of Dependence</i>	372
<i>Fear</i>	329	<i>Adaptations Implicated in Emotional-Motivational</i>	
<i>Anxiety</i>	330	<i>Dependence</i>	372
<i>Anxiety and Emotional Memory</i>	330	<i>Other Mechanisms Related to Tolerance</i>	374
<i>Mood Regulation</i>	332	<i>Specificity of Neural Substrates</i>	
Pharmacology of Anxiety and Anxiety Disorders	332	<i>That Underlie Dependence</i>	374
<i>Molecular Pharmacology of the GABA_A Receptor</i>	333	<i>Link Between Drug Craving and Relapse</i>	
<i>Effects of GABAergic Drugs on Anxiety</i>	334	<i>of Addiction</i>	374
<i>Tolerance and Dependence Associated With</i>		<i>Sensitization of Neural Processes May Underlie</i>	
<i>Benzodiazepines</i>	336	<i>Drug Craving</i>	375
<i>Nonbenzodiazepine Anxiolytics</i>	337	<i>Mechanisms of Sensitization</i>	375
<i>Treatment of Anxiety Disorders</i>	337	<i>Impact of Gene Expression on Long-Lasting</i>	
<i>Obsessive–Compulsive Disorder</i>	338	<i>Adaptations</i>	376
Pharmacology of Mood Disorders	338	<i>Adaptations in Neuronal Morphology</i>	
		<i>and Survival</i>	377
		<i>Adaptations Relevant to Conditioned Craving</i>	
		<i>and Relapse of Addiction</i>	378

Treatment of Addiction	379	<i>Sensitization</i>	437
<i>Psychostimulants</i>	379	<i>Neurogenic Inflammation</i>	439
<i>Opiates</i>	379	Processing of Pain-Related Information	
<i>Alcohol</i>	381	by the CNS	439
		<i>Dorsal Horn of the Spinal Cord</i>	439
17. HIGHER COGNITIVE FUNCTION		<i>Neurotransmitters and Receptors in the Dorsal Horn</i>	441
 AND PSYCHOSIS	383	<i>Multiple Pathways to the Brain</i>	443
Neuroanatomy of Higher Cognition	384	Endogenous Mechanisms of Analgesia	444
Working Memory and Cognitive Abstraction	385	<i>Endogenous Opioids and Related Peptides</i>	444
Psychosis and Schizophrenia	386	<i>Descending Analgesic Pathways</i>	445
<i>Pathophysiology of Schizophrenia</i>	388	Analgesic Medications	446
Pharmacology of Perception and Integration	392	<i>Opiates</i>	446
<i>Drugs That Induce Psychosis</i>	392	<i>Nonsteroidal Antiinflammatory Drugs</i>	448
<i>Drugs That Reduce Psychosis</i>	398	<i>Nonopioid, Non-NSAID Analgesics</i>	449
		Clinical Pain Syndromes	449
18. SLEEP, AROUSAL, AND ATTENTION	409	<i>Neuropathic Pain</i>	450
Historical Overview	410	<i>Migraine</i>	450
Normal Human Sleep	411	20. MEMORY AND DEMENTIAS	453
Ontogeny of Sleep	411	Memory	454
Functions of Sleep	413	<i>Declarative and Nondeclarative Memory</i>	454
Neural Substrates of Sleep	414	<i>The Medial Temporal Lobe System</i>	455
<i>NREM Sleep</i>	414	Synaptic Plasticity: How Do Neurons Remember?	457
<i>REM Sleep</i>	414	<i>LTP and Memory Formation</i>	458
<i>Association of Adenosine With Sleep</i>	416	<i>Other Forms of Synaptic Plasticity</i>	462
Circadian and Homeostatic Control		<i>Beyond LTP: Why We Remember</i>	
of the Sleep–Wake Cycle	416	<i>What We Remember</i>	463
<i>Molecular Control of Circadian Rhythms</i>	417	<i>Pharmacologic Regulation of Memory</i>	465
Neurobiology of Arousal	418	Disorders of Memory	465
Sleep Disorders	419	Alzheimer Disease and Related Dementias	468
<i>Dysomnias</i>	419	<i>Pathology</i>	469
<i>Parasomnias</i>	421	<i>Genetic and Molecular Mechanisms</i>	470
Pharmacology of Sleep–Wake Disorders	421	<i>Role of APP and Aβ</i>	470
<i>Benzodiazepines</i>	421	<i>Role of Presenilins</i>	472
<i>Nonbenzodiazepine Sedative–Hypnotic Agents</i>	423	<i>Role of ApoE</i>	472
<i>Drugs That Increase Alertness</i>	425	<i>Role of Other Genes</i>	473
Attention	426	<i>Treatment</i>	474
Cortical Responsiveness to Stimuli	426	21. SEIZURES AND STROKE	479
Orchestration of Attentional Processes	427	Stroke	480
Attention Deficit and Hyperactivity Disorder	429	Basic Mechanisms of Excitotoxicity	480
Neurobiologic Mechanisms of ADHD	429	<i>Depletion of Energy Stores</i>	482
Treatment of ADHD	430	<i>Failure of Ion Pumps</i>	482
		<i>Depolarization and Firing</i>	482
19. PAIN	433	<i>Increases in Intracellular Ca²⁺</i>	482
Processing of Pain-Related Information		<i>Activation of Enzymes by Ca²⁺</i>	482
by the Peripheral Nervous System	434	<i>Acidosis</i>	484
<i>Primary Afferent Nociceptors</i>	434	<i>Formation of Free Radicals</i>	484
		<i>Apoptosis</i>	485

Treatment of Stroke	486	<i>Genetic Influences</i>	497
<i>The Peri-infarct Area:</i>		<i>Neural Death, Neurogenesis, and Neural Sprouting:</i>	
<i>An Important Treatment Target</i>	486	<i>Keys to Epileptogenesis?</i>	498
<i>Restoring Blood Supply</i>	486	Treatment of Epilepsy	499
<i>Minimizing Ca²⁺ Influx into Cells</i>	490	<i>Drugs That Enhance Na⁺ Channel</i>	
<i>Reducing Free Radical Damage</i>	490	<i>Inactivation</i>	500
<i>Promoting Neural Recovery</i>	490	<i>Drugs That Enhance Inhibitory GABAergic</i>	
Seizures and Epilepsy	490	<i>Transmission</i>	501
<i>Generation of a Seizure</i>	492	<i>Rhyme and Reason:</i>	
<i>Classification of Seizures</i>	493	<i>Determining the Appropriate Drug</i>	502
<i>What Causes Epilepsy?</i>	497	Index	505

PART 1

Fundamentals of Neuropharmacology

CHAPTERS

- 1 **BASIC PRINCIPLES OF NEUROPHARMACOLOGY**
- 2 **NEURONS AND GLIA**
- 3 **ELECTRICAL EXCITABILITY OF NEURONS**
- 4 **SYNAPTIC TRANSMISSION**
- 5 **SIGNAL TRANSDUCTION PATHWAYS IN THE BRAIN**
- 6 **SIGNALING TO THE NUCLEUS**



Ca²⁺

